Dianthus Therapeutics Inc. (DNTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dianthus Therapeutics Inc. (DNTH) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.86 Million) by net assets ($1.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dianthus Therapeutics Inc. balance sheet independence to measure how much of total assets are equity-financed.
Dianthus Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Dianthus Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DNTH capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Dianthus Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dianthus Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
0.000x |
|
Kanzhun Ltd ADR
NASDAQ:BZ
|
0.066x |
|
Osisko Gold Ro
TO:OR
|
0.059x |
|
Shenzhen New Industries Biomedical
SHE:300832
|
0.069x |
|
GalaxyCore Inc
SHG:688728
|
0.020x |
|
Artemis Gold Inc
V:ARTG
|
0.196x |
|
Youngor Group Co Ltd
SHG:600177
|
0.021x |
|
Turkcell Iletisim Hizmetleri AS ORD
IS:TCELL
|
0.103x |
Annual Cash Flow Conversion Efficiency for Dianthus Therapeutics Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Dianthus Therapeutics Inc. from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Dianthus Therapeutics Inc. (DNTH) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $493.40 Million | $-129.06 Million | -0.262x | -17.93% |
| 2024-12-31 | $352.48 Million | $-78.18 Million | -0.222x | -1.61% |
| 2023-12-31 | $168.87 Million | $-36.86 Million | -0.218x | +44.69% |
| 2022-12-31 | $73.66 Million | $-29.07 Million | -0.395x | -14.48% |
| 2021-12-31 | $172.67 Million | $-59.53 Million | -0.345x | +22.51% |
| 2020-12-31 | $143.91 Million | $-64.02 Million | -0.445x | -10.00% |
| 2019-12-31 | $141.19 Million | $-57.10 Million | -0.404x | -40.63% |
| 2018-12-31 | $145.65 Million | $-41.89 Million | -0.288x | +35.00% |
| 2017-12-31 | $50.32 Million | $-22.26 Million | -0.442x | +38.73% |
| 2016-12-31 | $9.04 Million | $-6.53 Million | -0.722x | -- |
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more